Capital Research Global Investors
Position in INBX — Inhibrx Biosciences, Inc.
CIK 1422848
Los Angeles, CA
Position in INBX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$34,398,987
+$7,987,884 QoQ
Shares Held
363,050
-7.6% QoQ
Ownership
2.47%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#12
of 161 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INBX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capital Research Global Investors holds $14,161,458,348 across 17 Biotechnology names. INBX ranks #15 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
19,490,637 | $9,681,584,117 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,750,699 | $2,935,252,919 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
3,504,387 | $200,521,024 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
5,344,701 | $199,197,006 | |
| 5 | TECH |
BIO-TECHNE Corp
|
2,621,890 | $185,236,528 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
1,532,303 | $170,131,602 | |
| 7 | KYMR |
Kymera Therapeutics, Inc.
|
1,388,881 | $159,262,984 | |
| 8 | CYTK |
Cytokinetics Inc
|
1,686,625 | $143,683,583 |
All Filings in INBX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $34,398,987 | 363,050 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $26,411,103 | 392,847 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $33,304,425 | 421,575 | Shares | Defined | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||